全文获取类型
收费全文 | 20665篇 |
免费 | 2615篇 |
国内免费 | 374篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 799篇 |
妇产科学 | 398篇 |
基础医学 | 1882篇 |
口腔科学 | 194篇 |
临床医学 | 2383篇 |
内科学 | 7189篇 |
皮肤病学 | 349篇 |
神经病学 | 1799篇 |
特种医学 | 344篇 |
外科学 | 2432篇 |
综合类 | 1312篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 1609篇 |
眼科学 | 715篇 |
药学 | 874篇 |
2篇 | |
中国医学 | 188篇 |
肿瘤学 | 1052篇 |
出版年
2024年 | 55篇 |
2023年 | 451篇 |
2022年 | 258篇 |
2021年 | 471篇 |
2020年 | 440篇 |
2019年 | 202篇 |
2018年 | 776篇 |
2017年 | 783篇 |
2016年 | 846篇 |
2015年 | 817篇 |
2014年 | 747篇 |
2013年 | 1019篇 |
2012年 | 1466篇 |
2011年 | 1490篇 |
2010年 | 958篇 |
2009年 | 923篇 |
2008年 | 1288篇 |
2007年 | 1233篇 |
2006年 | 1070篇 |
2005年 | 1186篇 |
2004年 | 1503篇 |
2003年 | 1309篇 |
2002年 | 1006篇 |
2001年 | 811篇 |
2000年 | 304篇 |
1999年 | 330篇 |
1998年 | 373篇 |
1997年 | 296篇 |
1996年 | 141篇 |
1995年 | 101篇 |
1994年 | 86篇 |
1993年 | 108篇 |
1992年 | 90篇 |
1991年 | 55篇 |
1990年 | 61篇 |
1989年 | 59篇 |
1988年 | 56篇 |
1987年 | 45篇 |
1986年 | 39篇 |
1985年 | 23篇 |
1984年 | 20篇 |
1983年 | 19篇 |
1982年 | 20篇 |
1981年 | 23篇 |
1980年 | 14篇 |
1977年 | 13篇 |
1975年 | 13篇 |
1974年 | 18篇 |
1968年 | 17篇 |
1928年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Paul E. Drawz Arnold B. Alper Amanda H. Anderson Carolyn S. Brecklin Jeanne Charleston Jing Chen Rajat Deo Michael J. Fischer Jiang He Chi-yuan Hsu Yonghong Huan Martin G. Keane John W. Kusek Gail K. Makos Edgar R. Miller III Elsayed Z. Soliman Susan P. Steigerwalt Jonathan J. Taliercio Raymond R. Townsend Matthew R. Weir Jackson T. Wright Jr. Dawei Xie Mahboob Rahman the Chronic Renal Insufficiency Cohort Study Investigators 《Clinical journal of the American Society of Nephrology》2016,11(4):642-652
Background and objectives
Masked hypertension and elevated nighttime BP are associated with increased risk of hypertensive target organ damage and adverse cardiovascular and renal outcomes in patients with normal kidney function. The significance of masked hypertension for these risks in patients with CKD is less well defined. The objective of this study was to evaluate the association between masked hypertension and kidney function and markers of cardiovascular target organ damage, and to determine whether this relationship was consistent among those with and without elevated nighttime BP.Design, setting, participants, & measurements
This was a cross-sectional study. We performed 24-hour ambulatory BP in 1492 men and women with CKD enrolled in the Chronic Renal Insufficiency Cohort Study. We categorized participants into controlled BP, white-coat, masked, and sustained hypertension on the basis of clinic and 24-hour ambulatory BP. We obtained echocardiograms and measured pulse wave velocity in 1278 and 1394 participants, respectively.Results
The percentages of participants with controlled BP, white-coat, masked, and sustained hypertension were 49.3%, 4.1%, 27.8%, and 18.8%, respectively. Compared with controlled BP, masked hypertension independently associated with low eGFR (−3.2 ml/min per 1.73 m2; 95% confidence interval, −5.5 to −0.9), higher proteinuria (+0.9 unit higher in log2 urine protein; 95% confidence interval, 0.7 to 1.1), and higher left ventricular mass index (+2.52 g/m2.7; 95% confidence interval, 0.9 to 4.1), and pulse wave velocity (+0.92 m/s; 95% confidence interval, 0.5 to 1.3). Participants with masked hypertension had lower eGFR only in the presence of elevated nighttime BP (−3.6 ml/min per 1.73 m2; 95% confidence interval, −6.1 to −1.1; versus −1.4 ml/min per 1.73 m2; 95% confidence interval, −6.9 to 4.0, among those with nighttime BP <120/70 mmHg; P value for interaction with nighttime systolic BP 0.002).Conclusions
Masked hypertension is common in patients with CKD and associated with lower eGFR, proteinuria, and cardiovascular target organ damage. In patients with CKD, ambulatory BP characterizes the relationship between BP and target organ damage better than BP measured in the clinic alone. 相似文献992.
Neurobehavioral Deficits Consistent Across Age and Sex in Youth with Prenatal Alcohol Exposure 下载免费PDF全文
993.
994.
995.
Impact of interferon‐free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real‐life cohort 下载免费PDF全文
M. J. álvarez‐Ossorio R. Sarmento e Castro R. Granados J. Macías L. E. Morano‐Amado M. J. Ríos D. Merino E. N. álvarez A. Collado M. Pérez‐Pérez F. Téllez J. M. Martín J. Méndez J. A. Pineda K. Neukam the HEPAVIR‐DAA GEHEP‐MONO RIS‐HEP RIS‐HEP Study Groups 《Journal of viral hepatitis》2018,25(6):699-706
Little data are available on renal toxicity exerted by direct‐acting antivirals (DAAs) in real life. The aim of this study was to assess the impact of direct‐acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR) in clinical practise. From an international, prospective multicohort study, patients treated with DAAs for at least 12 weeks and with eGFR ≥30 mL/min per 1.73 m2 at baseline were selected. eGFR was determined using the CKD‐EPI formula. A total of 1131 patients were included; 658 (58%) were HIV/HCV‐coinfected patients. Among the 901 patients treated for 12 weeks, median (interquartile range) eGFR was 100 (87‐107) at baseline vs 97 (85‐105) mL/min per 1.73 m2 at week 12 of follow‐up (FU12) post‐treatment (P < .001). For HIV‐coinfected subjects who received tenofovir plus a ritonavir‐boosted HIV protease inhibitor (PI/r), baseline vs FU12 eGFR were 104 (86‐109) vs 104 (91‐110) mL/min per 1.73 m2 (P = .913). Among subjects receiving ombitasvir/paritaprevir with or without dasabuvir, eGFR did not show any significant change. Of 1100 subjects with eGFR >60 mL/min per 1.73 m2 at baseline, 22 (2%) had eGFR <60 mL/min per 1.73 m2 at FU12, but none presented with eGFR <30 mL/min per 1.73 m2. In conclusion, eGFR slightly declines during therapy with all‐oral DAAs and this effect persists up to 12 weeks after stopping treatment in subjects with normal to moderately impaired renal function, regardless of HIV status. Concomitant use of tenofovir plus PI/r does not seem to have an impact on eGFR. 相似文献
996.
997.
Ioanna Xanthopoulou Vasiliki-Maria Dragona Periklis Davlouros Costas Tsioufis Efstathios Iliodromitis Dimitrios Alexopoulos for the GRAPE-AF Investigators 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2018,32(2):191-196
Background
Approximately 5 to 7% of patients undergoing percutaneous coronary intervention (PCI) for the treatment of coronary artery disease require chronic oral anticoagulation (OAC) on top of aspirin and a P2Y12 receptor antagonist, mainly due to non-valvular atrial fibrillation (AF). The advent of non-vitamin K antagonist oral anticoagulants (NOACs) increased treatment options, while there is cumulative evidence that dual combination of a NOAC and a P2Y12 receptor antagonist attenuates risk of bleeding, compared to traditional triple therapy, consisting of a vitamin K antagonist (VKA), aspirin, and a P2Y12 receptor antagonist, without significantly compromising efficacy.Study Design
Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF, NCT 03362788) is an observational, nationwide study of non-valvular AF patients undergoing PCI, planning to enroll over 1-year period >?500 participants in 25 tertiary and non-tertiary PCI centers in Greece. Key data to be collected pre-discharge include demographics, detailed past medical history, and antithrombotic and concomitant treatment. Patients will be followed up at 1, 6, and 12 months post hospital discharge. Αt each follow-up visit, data on antithrombotic treatment, ischemic, bleeding, and adverse events will be collected. Study’s primary endpoint is clinically significant bleeding (Bleeding Academic Research Consortium, BARC ≥?2) at 12 months, between VKAs and NOACs-treated patients, analyzed using Cox proportional hazards models, by an intention-to-treat principle. An independent endpoint committee will adjudicate all clinical events.Conclusions
This study aims at providing “real-world” information on current antithrombotic treatment patterns and clinical outcome of patients with non-valvular AF undergoing PCI.998.
Food insecurity may lead to incomplete HIV viral suppression and less immune reconstitution among HIV/hepatitis C virus‐coinfected people 下载免费PDF全文
W Aibibula J Cox A‐M Hamelin EEM Moodie AI Naimi T McLinden MB Klein P Brassard the Canadian Co‐infection Cohort Co‐Investigators 《HIV medicine》2018,19(2):123-131
Objectives
The aim of this study was to determine the impact of food insecurity (FI) on HIV viral load and CD4 count among people coinfected with HIV and hepatitis C virus (HCV).Methods
This study was conducted using data from the Food Security & HIV‐HCV Sub‐Study of the Canadian Co‐Infection Cohort study. FI was measured using the adult scale of Health Canada's Household Food Security Survey Module and was classified into three categories: food security, moderate food insecurity and severe food insecurity. The association between FI, HIV viral load, and CD4 count was assessed using a stabilized inverse probability weighted marginal structural model.Results
A total of 725 HIV/HCV‐coinfected people with 1973 person‐visits over 3 years of follow‐up contributed to this study. At baseline, 23% of participants experienced moderate food insecurity and 34% experienced severe food insecurity. The proportion of people with undetectable HIV viral load was 75% and the median CD4 count was 460 [interquartile range (IQR): 300–665] cells/μL. People experiencing severe food insecurity had 1.47 times [95% confidence interval (CI): 1.14, 1.88] the risk of having detectable HIV viral load and a 0.91‐fold (95% CI: 0.84, 0.98) increase in CD4 count compared with people who were food secure.Conclusions
These findings provide evidence of the negative impact of food insecurity on HIV viral load and CD4 count among HIV/HCV‐coinfected people.999.
1000.
Tjallie van der Kooi Hugo Sax Didier Pittet Jaap van Dissel Birgit van Benthem Bernhard Walder Vanessa Cartier Lauren Clack Sabine de Greeff Martin Wolkewitz Stefanie Hieke Hendriek Boshuizen Jan van de Kassteele Annemie Van den Abeele Teck Wee Boo Magda Diab-Elschahawi Uga Dumpis Camelia Ghita Susan FitzGerald Tatjana Lejko Kris Leleu Mercedes Palomar Martinez Olga Paniara Márta Patyi Paweł Schab Annibale Raglio Emese Szilágyi Mirosław Ziętkiewicz Albert W. Wu Hajo Grundmann Walter Zingg On behalf of the PROHIBIT consortium 《Intensive care medicine》2018,44(1):48-60